Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | THPO | P40225 | 1/20 | 0.40 |
| ▸ | MARK3 | P27448 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 2/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.35 |
| ▸ | LDHA | P00338 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2342685 | 0.87 | ELANE (0.48) | EGLN1GAAALDH1A1CYP3A4MARK3 | |
| SCHEMBL9469392 | 0.81 | PGR (0.56) | EGLN1GAAALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL9469489 | 0.79 | EGLN1 (0.43) | EGLN1GAAALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL9839213 | 0.78 | ELANE (0.59) | EGLN1ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL9469840 | 0.77 | EGLN1 (0.42) | EGLN1GAAALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL8687319 | 0.76 | LMNA (0.35) | GAAALDH1A1KDM4E | |
| SCHEMBL1149635 | 0.75 | EGLN1 (0.43) | EGLN1GAAALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL2590024 | 0.75 | CYP19A1 (0.38) | GAAALDH1A1MARK3MGLLKAT2B | |
| SCHEMBL9211380 | 0.75 | ALDH1A1 (0.70) | EGLN1ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL9469343 | 0.75 | EGLN1 (0.41) | EGLN1GAAALDH1A1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580813-B2 | Cyclic azaindole-3-carboxamides, their preparation and their use as pharmaceuticals | SANOFI (FR) | 2013-11-12 | — | — | US | disclosed |
| EP-2240482-B1 | CYCLIC AZAINDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2013-07-17 | — | — | EP | disclosed |
| US-8008491-B2 | poly(adenosine 5'-diphosphate ribose) polymerase inhibitors such as 1-phenyl-2-(piperazin-1-yl)-1,3-dihydropyrrolo[2,3-b]pyridine-3-carboxaldehyde, used in the treatment and/or prevention central nervous system and cardiovascular disorders | AVENTIS PHARMACEUTICALS, INC. (US) | 2011-08-30 | — | — | US | disclosed |
| US-20110039861-A1 | CYCLIC AZAINDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2011-02-17 | — | — | US | disclosed |
| EP-2240482-A1 | CYCLIC AZAINDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2010-10-20 | — | — | EP | disclosed |
| WO-2009095162-A1 | CYCLIC AZAINDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2009-08-06 | — | — | WO | disclosed |
| US-20080255350-A1 | SUBSTITUTED AZA-INDOLES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | AVENTIS PHARMACEUTICALS INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-7405300-B2 | Substituted indoles as inhibitors of poly (ADP-ribose) polymerase (PARP) | AVENTIS PHARMAVEUTICALS INC. (US) | 2008-07-29 | — | — | US | disclosed |
| EP-1663202-A1 | SUBSTITUTED INDOLES AS INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE (PARP) | Aventis Pharmaceuticals, Inc. (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005023246-A1 | SUBSTITUTED INDOLES AS INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE (PARP) | AVENTIS PHARMACEUTICALS INC. (US) | 2005-03-17 | — | — | WO | disclosed |
| US-20050054631-A1 | Substituted indoles as inhibitors of poly (ADP-ribose) polymerase (PARP) | AVENTIS PHARMACEUTICALS INC. (US) | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054631-A1 | Substituted indoles as inhibitors of poly (ADP-ribose) polymerase (PARP) | PARP1, PARP11, PARP3 | EGLN1 503/4885GAA 2614/4885ALDH1A1 449/4885 |
| US-20080255350-A1 | SUBSTITUTED AZA-INDOLES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | PARP1, PARP11, PARP15 | EGLN1 694/4885GAA 1923/4885ALDH1A1 304/4885 |
| US-20110039861-A1 | CYCLIC AZAINDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | REN, PM20D2, CDK20 | EGLN1 3332/4885GAA 1820/4885ALDH1A1 2609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.